Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction

Toxicology and Applied Pharmacology

Volumn 267, Issue 1, 2013, Pages 95-103

  Fang, Xian Ying ^a   Chen, Wei ^a   Fan, Jun Ting ^b   Song, Ran ^a   Wang, Lu ^a   Gu, Yan Hong ^c   Zeng, Guang Zhi ^b   Shen, Yan ^a   Wu, Xue Feng ^a   Tan, Ning Hua ^b   Xu, Qiang ^a   Sun, Yang ^a  

^a NANJING UNIVERSITY   (China)

^b KUNMING INSTITUTE OF BOTANY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cyclopeptide; Mitochondrial apoptosis pathway; PI3K AKT; RA V

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; CYTOCHROME C; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RA V PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MITOCHONDRIA; PEPTIDES, CYCLIC; PLANT EXTRACTS; PROTEIN INTERACTION MAPPING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

MURINAE;

EID: 84872258640     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.12.010     Document Type: Article

References (40)

1. Calleja V., Laguerre M., Parker P.J., Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol. 2009, 7:e17.
2. Chakraborty A., Koldobskiy M.A., Bello N.T., Maxwell M., Potter J.J., Juluri K.R., Maag D., Kim S., Huang A.S., Dailey M.J., Saleh M., Snowman A.M., Moran T.H., Mezey E., Snyder S.H. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell 2010, 143:897-910.
3. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., Franklin R.A., McCubrey J.A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17:590-603.
4. Colombo G., Curnis F., De Mori G.M., Gasparri A., Longoni C., Sacchi A., Longhi R., Corti A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem. 2002, 277:47891-47897.
5. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011. CA Cancer J. Clin. 2011, 61:408-418.
6. Di Cosimo S., Baselga J. Targeted therapies in breast cancer: where are we now?. Eur. J. Cancer 2008, 44:2781-2790.
7. Fan J.T., Su J., Peng Y.M., Li Y., Li J., Zhou Y.B., Zeng G.Z., Yan H., Tan N.H. Rubiyunnanins C-H, cytotoxic cyclic hexapeptides from Rubia yunnanensis inhibiting nitric oxide production and NF-kappaB activation. Bioorg. Med. Chem. 2010, 18:8226-8234.
8. Findlay M., von Minckwitz G., Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann. Oncol. 2008, 19:212-222.
9. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
10. Fuchs Y., Steller H. Programmed cell death in animal development and disease. Cell 2011, 147:742-758.
11. Gao J., Morgan W.A., Sanchez-Medina A., Corcoran O. The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells. Toxicol. Appl. Pharmacol. 2011, 254:221-228.
12. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005, 55:178-194.
13. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
14. Hitomi J., Katayama T., Eguchi Y., Kudo T., Taniguchi M., Koyama Y., Manabe T., Yamagishi S., Bando Y., Imaizumi K., Tsujimoto Y., Tohyama M. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J. Cell Biol. 2004, 165:347-356.
15. Hsin I.L., Hsiao Y.C., Wu M.F., Jan M.S., Tang S.C., Lin Y.W., Hsu C.P., Ko J.L. Lipocalin 2, a new GADD153 target gene, as an apoptosis inducer of endoplasmic reticulum stress in lung cancer cells. Toxicol. Appl. Pharmacol. 2012, 263:330-337.
16. Itokawa H., Takeya K., Mori N., Hamanaka T., Sonobe T., Mihara K. Isolation and antitumor activity of cyclic hexapeptides isolated from Rubiae radix. Chem. Pharm. Bull. (Tokyo) 1984, 32:284-290.
17. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
18. Jo M., Park M.H., Kollipara P.S., An B.J., Song H.S., Han S.B., Kim J.H., Song M.J., Hong J.T. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol. Appl. Pharmacol. 2012, 258:72-81.
19. Jung K.H., Choi M.J., Hong S., Lee H., Hong S.W., Zheng H.M., Lee H.S., Hong S.S. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway. Cancer Lett. 2012, 316:187-195.
20. Lacroix M., Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 2004, 83:249-289.
21. Lavrik I.N., Golks A., Krammer P.H. Caspases: pharmacological manipulation of cell death. J. Clin. Invest. 2005, 115:2665-2672.
22. Li J.W., Vederas J.C. Drug discovery and natural products: end of an era or an endless frontier?. Science 2009, 325:161-165.
23. Liu J.J., Lin M., Yu J.Y., Liu B., Bao J.K. Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett. 2011, 300:105-114.
24. Luo Q., Gu Y., Zheng W., Wu X., Gong F., Gu L., Sun Y., Xu Q. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicol. Appl. Pharmacol. 2011, 251:130-136.
25. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell 2011, 21:92-101.
26. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., Fujii T., Kuwano M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004, 3:465-472.
27. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
28. Rasheva V.I., Domingos P.M. Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis 2009, 14:996-1007.
29. Ribeiro J.T., Macedo L.T., Curigliano G., Fumagalli L., Locatelli M., Dalton M., Quintela A., Carvalheira J.B., Manunta S., Mazzarella L., Brollo J., Goldhirsch A. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. Ann. Oncol. 2012, 23:547-555.
30. Song R., Qian F., Li Y.P., Sheng X., Cao S.X., Xu Q. Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo. PLoS One 2009, 4:e4450.
31. Sonoda Y., Matsumoto Y., Funakoshi M., Yamamoto D., Hanks S.K., Kasahara T. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J. Biol. Chem. 2000, 275:16309-16315.
32. Sun Y., Qin Y., Gong F.Y., Wu X.F., Hua Z.C., Chen T., Xu Q. Selective triggering of apoptosis of concanavalin A-activated T cells by fraxinellone for the treatment of T-cell-dependent hepatitis in mice. Biochem. Pharmacol. 2009, 77:1717-1724.
33. Sun Y., Wu X.X., Yin Y., Gong F.Y., Shen Y., Cai T.T., Zhou X.B., Wu X.F., Xu Q. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. Biochem. Pharmacol. 2010, 79:229-238.
34. Tan N.H., Zhou J. Plant cyclopeptides. Chem. Rev. 2006, 106:840-895.
35. Tuma R.S. Three molecularly targeted drugs tested in kidney cancer clinical trials. J. Natl. Cancer Inst. 2004, 96:1270-1271.
36. 2+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol. Cancer Ther. 2011, 10:461-471.
37. Xie P., Kondeti V.K., Lin S., Haruna Y., Raparia K., Kanwar Y.S. Role of extracellular matrix renal tubulo-interstitial nephritis antigen (TINag) in cell survival utilizing integrin (alpha)vbeta3/focal adhesion kinase (FAK)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B-serine/threonine kinase (AKT) signaling pathway. J. Biol. Chem. 2011, 286:34131-34146.
38. Yang F., Jove V., Xin H., Hedvat M., Van Meter T.E., Yu H. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol. Cancer Res. 2010, 8:35-45.
39. Yuan H., Pupo M.T., Blois J., Smith A., Weissleder R., Clardy J., Josephson L. A stabilized demethoxyviridin derivative inhibits PI3 kinase. Bioorg. Med. Chem. Lett. 2009, 19:4223-4227.
40. Yue G.G., Fan J.T., Lee J.K., Zeng G.Z., Ho T.W., Fung K.P., Leung P.C., Tan N.H., Lau C.B. Cyclopeptide RA-V inhibits angiogenesis by down-regulating ERK1/2 phosphorylation in HUVEC and HMEC-1 endothelial cells. Br. J. Pharmacol. 2011, 164:1883-1898.